Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
“GENVIRO WILL BE MADE IN KOREA. TEST STRIPS WILL BE MADE IN USA.”
“The kits will be manufactured for DECN in Korea by its contract manufacturer, the same company that manufactures our diabetic test strips - - THE SAME (KOREAN) COMPANY THAT MANUFACTURES OUR DIABETIC TEST STRIPS. While the manufacturing will occur in Korea, the test strip is 100% of American design.” https://www.marketwatch.com/press-release/decn-finalizes-fda-pre-eua-version-of-its-genviro-screening-covid-19-swift-kit-providing-results-in-15-seconds-using-only-10-20-microliters-whole-blood-2020-03-23
LOOK AT TOP OF PAGE. SAYS, THE BIO AND THEY ARE FDA REGISTERED IN FULL CONTROL.
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?rid=191768
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm
The Bio would not make the claim if it were not true. The tests and results were conducted by THE BIO. Berman is irrelevant. He talks too much. But the test results confirm and verify the technology. And The Bio is in full control. THE BIO CAN REPLACE BERMAN IF NEEDED. The Bio is the parent company. And The Bio owns DECISION DIAGNOSTICS, PHARMA TECH SOLUTIONS, THE GENVIRO and all GLUCOSE TESTS. BERMAN JUST WORKS THERE.
THERE Is KOREAN BACKING. “Korean venture funds and angel investors."
Keith Berman, CEO of Decision Diagnostics Corp., stated "Daniel Kim and I are thrilled to be joining the Board of Directors at "The Bio," a venture funded corporation located in South Korea, that is owned and financed by prominent Korean venture funds and angel investors."
READ: WE HAVE ANGEL INVESTORS” and KOREAN VENTURE FUNDS.?? ?? ?? THIS IS HUGE. ?? AND THEY OWN THE KOREAN COMPANY AND MANAGE THE FDA CLINICAL TRIALS.
Decision Diagnostics Corp. Announces Two Key Managers to the Board of Its Korean Partner The Bio Co, Ltd
https://www.accesswire.com/505019/Decision-Diagnostics-Corp-Announces-Election-of-Two-Key-Managers-to-the-Board-of-Its-Korean-Partner-The-Bio-Co-Ltd
DECISION DIAGNOSTICS IS BACKED AND FUNDED BY KOREAN VENTURE FUNDS AND ANGEL INVESTORS
https://www.accesswire.com/505019/Decision-Diagnostics-Corp-Announces-Election-of-Two-Key-Managers-to-the-Board-of-Its-Korean-Partner-The-Bio-Co-Ltd
“The Bio" currently manufacturers DECN's GenUltimate!, GenSure! and PetSure! products for the U.S. and International markets, along with managing the clinical trials....”
“Decision Diagnostics is excited to announce that two key executives, CEO Keith Berman and exclusive agent to DECN for Asia Daniel Y. Kim, have been elected to the Board of Directors of The Bio Co. Ltd., the company's partner for the manufacturing of and development of its test strips and meters. Decision Diagnostics may also have a third director elected at an upcoming date.”
“Keith Berman, CEO of Decision Diagnostics Corp., stated "Daniel Kim and I are thrilled to be joining the Board of Directors at "The Bio," a venture funded corporation located in South Korea, that is owned and financed by prominent Korean venture funds and angel investors."
“The Bio" currently manufacturers DECN's GenUltimate!, GenSure! and PetSure! products for the U.S. and International markets, along with managing the clinical trials....”
https://www.accesswire.com/505019/Decision-Diagnostics-Corp-Announces-Election-of-Two-Key-Managers-to-the-Board-of-Its-Korean-Partner-The-Bio-Co-Ltd
When I saw the blood hematocrit results the impedance levels were better than 98%, modestly, and they were all consistent. When we see the COVID-19 sample-tests, I am absolutely certain that the result consistency will duplicate in the upper 98%s, 99%s, even 100%. I know what I saw by the blood alone. And those impedance values were spot, dead on accurate. I personally do not approve of Berman’s Excessive press releases. But the test results were dead on accurate and consistent. This you can be sure of.
EIS REVOLUTION HAS BEGUN
https://pharmatechsolutions.co/genviro.html
https://www.sensdx.eu/products/sars-cov-2-sensdx-assay/
Johns Hopkins Medicine, EIS COVID-19 Test. https://www.electrochem.org/ecs-blog/ecs-adapts-advances-arroyo-curras/
FDA Approves EIS System Nevisense 3.0 for the Early Detection of Melanoma
May 01, 2020
https://www.targetedonc.com/view/fda-approves-eis-sytem-nevisense-3-0-for-the-early-detection-of-melanoma
GAME OVER: FDA APPROVAL, IMMINENT.
See top of page, “NEVISENSE ELECTRICAL IMPEDANCE SPECTROMETER” :
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfrl/TextResults.cfm?dls=31&q=SW1wZWRhbmNlIHNwZWN0cm9zY29weQ==&pf=0&pn=10&sc=ena
FDA Approves EIS System Nevisense 3.0 for the Early Detection of Melanoma
May 01, 2020
https://www.targetedonc.com/view/fda-approves-eis-sytem-nevisense-3-0-for-the-early-detection-of-melanoma
https://scibase.com/
It says: “within seconds.”
https://scibase.com/the-eis-technology/
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfrl/rl.cfm?lid=541148&lpcd=ONV
A breakthrough in non-invasive detection of melanoma:
https://scibase.com/the-nevisense-product/
Look what I found! We will be there too.
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfrl/rl.cfm
SensDx COVID-19 (“EIS”) rapid testing solution for clinical and non-clinical.
The assay is designed for professional use by medical or paramedical personnel. The procedure is easy to use and does not require any specific training.
The following is required to perform an assay:
Mobi SensDx electrochemical impedance spectroscopy reader
https://www.sensdx.eu/products/sars-cov-2-sensdx-assay/
“Glucose IVD, kit, electrometry“
“Home-use/point-of-care glucose rapid test/blood pressure system analyser”
“Glucose IVD, kit, electrometry“
Click + on right side https://accessgudid.nlm.nih.gov/devices/search?query=genultimate+
1). Device IDs:
00867396000324 (Primary)
10867396000321 (Package)
20867396000328 (Package)
00868906000131 (Unit of Use)
Catalog Number: 100-10
GMDN Terms:
“Home-use/point-of-care glucose rapid test/blood pressure system analyser”
2). Device IDs:
00850015460036 (Primary)
00868906000131 (Unit of Use)
10850015460033 (Package)
20850015460030 (Package)
Catalog Number:
GMDN Terms:
“Glucose IVD, kit, electrometry“
3). Device IDs:
20860002137937 (Package)
10860002137930 (Package)
00860002137933 (Primary)
00860002137940 (Unit of Use)
Catalog Number:
GMDN Terms:
“Glucose IVD, kit, electrometry”
4). Device IDs:
10860002137923 (Package)
00860002137926 (Primary)
00860002137940 (Unit of Use)
10860002137916 (Package)
Catalog Number:
GMDN Terms:
“Glucose IVD, kit, electrometry“
Click the + on the right: https://accessgudid.nlm.nih.gov/devices/search?query=00860002137971
The words “IVD, Kit, electrometry” are key. “Glucose IVD, kit, electrometry.”
Start searching: https://accessgudid.nlm.nih.gov/
https://accessgudid.nlm.nih.gov/devices/00867396000324
https://www.google.com/search?client=safari&channel=iphone_bm&ei=Q_PbXpGnNsGf_QaQhqOoDA&q=PHARMA+TECH+SOLUTIONS%2C+INC.+access+gudid&oq=PHARMA+TECH+SOLUTIONS%2C+INC.+access+gudid&gs_lcp=ChNtb2JpbGUtZ3dzLXdpei1zZXJwEAMyBwghEAoQoAE6BwgAEEcQsAM6AggpOgUIIRCgAToFCCEQqwI6CAghEBYQHRAeOgYIABAWEB5QvqoBWMPeAWDr6wFoAnAAeACAAYoDiAGqGJIBCDMuMTAuMC40mAEAoAEB&sclient=mobile-gws-wiz-serp
Some people think that DECN has “Serology” tests. They are wrong. DECN DOES NOT have SEROLOGY tests. Since those people are wrong about the type of test, they are also wrong about DECN and “GENVIRO SWIFT.”
THE TECHNOLOGY IS SOLID GOLD, PERIOD.
“As also reported in our recent review (Arduini et al., 2017), many electrochemical (bio)sensors have been developed for biomedical applications (Huang X. et al., 2017; Huang Y. et al., 2017; Jiang et al., 2017). This manuscript was inspired by the unequal use of sensors in the pharmaceutical sector, where optical devices are abundant while the electrochemical ones are still in their infancy, despite their potential has been already demonstrated. In particular, the convergence of innovative technologies in the design of advanced tools will be reported to boost the progress in electrochemical sensors devoted to the drug production chain and personalized healthcare.” https://www.frontiersin.org/articles/10.3389/fbioe.2020.00339/full
A new virus diagnostic revolution is beginning and Decision Diagnostics is breaking ground.
Page 43. “CoV-2 virus detection .... glucometer (f).”
These devices have been allowing for quantitative and rapid detection of almost any type of analyte in a short time and with point-of-care (PoC) readout. Despite, the consumer market came to know almost only the glucometer, these systems have a huge applicability and the potential to overcome the limitations of their widespread optical cousins, the Lateral Flow Assays (LFAs) overall in terms of sensitivity.
Situations like the one we are living with SARS-CoV-2 virus, from local outbreaks to pandemics would radically change their impact on our societies if these tools would come to be rapidly available. The easy connection of the readout systems to the web would allow real-time monitoring of the spread, planning of effective actions to limit it, modelling and obtaining accurate prevision to minimize the economical and societal impacts.”
http://www.confstreaming.com/Biosensors2020/Biosensors2020_AbstractsBook.pdf
Barchart shows 100% float. https://www.barchart.com/stocks/quotes/DECN/profile
“We...describe a simple device that can potentially detect any virus between nanogap electrodes using nonlinear impedance spectroscopy......Here we proposed a virus detection method by nonlinear impedance spectroscopy under a strong electric field between two nanogap electrodes.” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563260/
“..electrochemical impedance is one of the most effective methods for detection of interactions between the antigen and the antibody. ... Attachment of the antibodies directly to the surface of the electrode is the most appropriate and most straightforward method for the present application.”
https://www.sciencedirect.com/science/article/abs/pii/S0925400518317684
$3.00 to $9.00 IMMINENT..
Journal of The Electrochemical Society
https://iopscience.iop.org/journal/1945-7111
The Electrochemical Society is a learned society (professional association) based in the United States that supports scientific inquiry in the field of electrochemistry and solid-state science and technology. The society membership comprises more than 8,000 scientists and engineers in over 70 countries worldwide who hold individual membership, as well as roughly 100 corporations and laboratories that hold corporate membership.
https://en.wikipedia.org/wiki/Electrochemical_Society
Electrochemical Society: https://www.electrochem.org/
Johns Hopkins Medicine, EIS COVID-19 Test.
https://www.electrochem.org/ecs-blog/ecs-adapts-advances-arroyo-curras/
Electrochemical impedance is very accurate and my research uncovered tons of substantial information and “current” (present) practical uses in various disciplines. Because the medical community is inclined towards using common diagnostic processes, it is also difficult to adopt new methods into their protocols. Diagnostic Diversification affords multiple methodologies, enhancing higher combined efficiency. This is not just about COVID-19 diagnosis. All pathogens and antigens and cells and organisms have unique electrical properties that can be impedimerically measured and identified as well. I’ll put this plainly; everything has electrical properties. SEE THE TWO LINKS, BELOW:
https://www.google.com/search?client=safari&channel=iphone_bm&ei=Ur3aXuuvL4mpytMPsvmBgA4&q=electrochemical+impedance+uses+&oq=electrochemical+impedance+uses+&gs_lcp=ChNtb2JpbGUtZ3dzLXdpei1zZXJwEAMyBggAEBYQHjoCCCk6BAgAEEc6BAgpEA06BAgAEEM6AggAOgIILjoFCCEQoAE6CAghEBYQHRAeUKWfAljnwwJgucYCaABwAXgAgAFXiAGcCJIBAjE3mAEAoAEB&sclient=mobile-gws-wiz-serp
https://www.google.com/search?q=electrochemical+impedance+uses&client=safari&channel=iphone_bm&prmd=ivsn&source=lnms&tbm=isch&sa=X&ved=2ahUKEwiA2Mav0-vpAhVfoXIEHdFrA0MQ_AUoAXoECA4QAQ&biw=375&bih=553
Disruptive technologies introduce new methods and processes that parent competition to existing companies using older technologies. The older technologies are not the same as the newer disruptive methods, but only different processes. Electrochemical Impedance Spectroscopy is nothing new. Electrochemical Impedance Spectroscopy saves time, it’s efficient, highly accurate and comparable to PCRs and faster. And PCRs are not 100%, With the exception of Codiagnostics.
http://www.confstreaming.com/Biosensors2020/Biosensors2020_AbstractsBook.pdf
Electrochemical impedance is also recognized by the Department of Health and Human Services as well as many international scientific bodies as can be seen by the link above from the Electrochemical Society. Please see the link:
https://stacks.cdc.gov/view/cdc/79494/cdc_79494_DS1.pdf
Just as the PCR is a technology to amplify nucleic acids, ELECTROCHEMICAL IMPEDANCE incorporates the entire organism’s electrical resistance as an identifying fingerprint. The FDA has many other applications for EIS devices and they are also globally recognized and used. Here’s another example. You’ll see “SensDx in the link as well as many other scientific, EIS illustrations : https://www.google.com/search?q=sensdx&client=safari&channel=iphone_bm&prmd=sniv&source=lnms&tbm=isch&sa=X&ved=2ahUKEwj49fr_xuvpAhVLhXIEHTd8DO8Q_AUoA3oECAkQAw&biw=375&bih=553#imgrc=M7HSZ5X8xMKx6M
Read link: http://www.confstreaming.com/Biosensors2020/Biosensors2020_AbstractsBook.pdf
Page 16: “In this talk, we describe a novel design that combines the traditional POC lateral flow strip tests and electrochemical impedance sensor with a commercialized smartphone-enabled glucometer for portable and quantitative detection of a non-glucose target. The concept is demonstrated by using an oxidative DNA damage biomarker and the protein biomarker of Zika virus. We establish a novel method that transforms the detection of the target to the detection of an nanozyme based converting enzymatic reaction for enabling quantitative analysis. Considering the inherent advantages of the personal glucose meter, the demonstration of this device, therefore, may inspire you the new opportunities for the development of an ASSURED i.e., affordable, sensitive, specific, user-friendly, rapid, robust, equipment free, and deliverable systems for COVID infection diseases.”
Page 18: “Diagnostic tests and devices based on electrochemical biosensors are being increasingly exploited as a valuable alternative to standard laboratory instrumentation for clinical diagnosis and as simple, inexpensive and point-of-care testing systems. Electrochemical biosensors are usually highly specific, sensitive, portable, and easy to operate. They are often designed to be affordable and to have a fast response that correlates well to different pathogen concentrations in different matrixes. Therefore, electrochemical biosensors hold the potential to contribute to the solution of a pandemic like we are living nowadays, especially regarding timely real-time detection, screening and diagnosis of pathogen-triggered diseases in working conditions, closer to the patient, in a reduced time-scale of testing and with minimal requirements of samples volume.”
Page 39: “Rapid and sensitive detection of SARS-CoV-2 in an affordable fashion is vital for the early diagnostics of the COVID-19. Moreover, with the inevitable emergence of the upcoming seasonal influenza (flu), it is highly important to differentiate influenza virus from SARS-CoV-2 in order for the healthcare professionals to prescribe the most appropriate medications. We have developed a novel biosensor for the concurrent detection of two short RNA strands (microRNA-21 and microRNA-141) that is being upgraded for the SARS-CoV-2 and H1N1 influenza virus.”
Page 43: “Abstract
Electrochemical biosensors have been impacting the research community since the 60s with the first generation of glucose oxidase biosensor. These devices have been allowing for quantitative and rapid detection of almost any type of analyte in a short time and with point-of-care (PoC) readout. Despite, the consumer market came to know almost only the glucometer, these systems have a huge applicability and the potential to overcome the limitations of their widespread optical cousins, the Lateral Flow Assays (LFAs) overall in terms of sensitivity.
SEE VISUAL EXAMPLES:
Figure 1: Schematic of the proposed SARS- CoV-2 virus detection strategies. Label-free detection of the impedance variation due to virus-aptamer binding (a) on the printed electrodes surface (b) readout by impedance commercially available app. (c). Reduction of NADH mediator access sites onto the electrode surface due to virus-aptamer binding (d) and readout by impedance (c) or commercially available glucometer (f). Labelled sandwich detection using glucose dehydrogenase as enzymatic label for signal amplification (e) and readout by glucometer (f).“
THE GLUCOSE METER DESIGN TEST FOR CORONAVIRUS IS VERY REAL. AND DECN BETTER HURRY UP. READ PAGE 16 IN THE LINK BELOW AND IN QUOTES. SPREAD THIS PDF EVERYWHERE. DECN IS CUTTING EDGE.
Read pp. 16, 41, 43 ELECTROCHEMICAL IMPEDANCE TECHNOLOGY
http://www.confstreaming.com/Biosensors2020/Biosensors2020_AbstractsBook.pdf
P. 16 — Perspectives of Biosensors Integrated Point of Care Testings for Personalized Screening of Coronavirus Disease
“In this talk, we describe a novel design that combines the traditional POC lateral flow strip tests and electrochemical impedance sensor with a commercialized smartphone-enabled glucometer for portable and quantitative detection of a non-glucose target. The concept is demonstrated by using an oxidative DNA damage biomarker and the protein biomarker of Zika virus. We establish a novel method that transforms the detection of the target to the detection of an nanozyme based converting enzymatic reaction for enabling quantitative analysis. Considering the inherent advantages of the personal glucose meter, the demonstration of this device, therefore, may inspire you the new opportunities for the development of an ASSURED i.e., affordable, sensitive, specific, user-friendly, rapid, robust, equipment free, and deliverable systems for COVID infection diseases.”
THOUGH I CAN APPRECIATE THE PRODUCT THE THIS COMPANY HAS AND THE ENTIRE PIPELINE, BASED ON THE PCR, I CAN SAY FOR SURE THAY THEY THEY DON’T FOR SHIT’S SURE HOW TO PRSENT IT OR KNOW HOW TO PRESENT THE PIPELINE FOR THEIR LIVES. JUST COME OUT WITH A VIDEO THAT COMPARES THE OTHERS AND SAY THAT YOU HAVE THE BEST PRODUCT IN THE WORLD AND PROVE IT. THESE GUYS ARE TALKING ABOUT MOSQUITOES?? WHAT THE F IN HELL IS GOING ON HERE?? NOW I’M PISSED OFF!! WE HAVE THE CORONA VIRUS, WE HAVE THE BEST PRODUCT IN THE WORLD AND THESE CODIAGNOSTICS CHARACHTERS ARE TALKING MOSQUITOES. SO THIS IS THE LAST TIME I BUY IN TO THIS COMPANY.
“LINK 2019COV Looks Like a Pandemic, Experts Say”
https://www.nytimes.com/2020/02/02/health/coronavirus-pandemic-china.html
PLEASE COPY AND POST TO STOCKTWITS AND YAHOO. Thank you.
“LINK 2019COV Looks Like a Pandemic, Experts Say”
https://www.nytimes.com/2020/02/02/health/coronavirus-pandemic-china.html
PLEASE COPY AND POST TO STOCKTWITS AND YAHOO. Thank you.
READ LINK: WHO says prepare for local coronavirus outbreaks in other countries
“The agency acted out of concern for poorer countries that might not be equipped to respond, said Galea. Such a declaration calls for a coordinated international response and can bring more money and resources.
WHO said it was especially concerned that some cases abroad involved human-to-human transmission.
“Countries need to get ready for possible importation in order to identify cases as early as possible and in order to be ready for a domestic outbreak control, if that happens,” Galea told The Associated Press.”
https://www.marketwatch.com/story/coronavirus-update-213-people-have-died-countries-recommend-against-travel-and-pilots-sue-over-continued-flights-to-china-2020-01-31
PLEASE COPY POST TO STOCKTWITS AND YAHOO
READ LINK: WHO (“WORLD HEALTH ORGANIZATION”) says prepare for local coronavirus outbreaks in other countries
“The agency acted out of concern for poorer countries that might not be equipped to respond, said Galea. Such a declaration calls for a coordinated international response and can bring more money and resources.
WHO said it was especially concerned that some cases abroad involved human-to-human transmission.
“Countries need to get ready for possible importation in order to identify cases as early as possible and in order to be ready for a domestic outbreak control, if that happens,” Galea told The Associated Press.”
https://www.marketwatch.com/story/coronavirus-update-213-people-have-died-countries-recommend-against-travel-and-pilots-sue-over-continued-flights-to-china-2020-01-31
PLEASE COPY AND POST TO YAHOO AND STOCKTWITS.